Noticias de HALO_US
Noticias del mercado
Últimas noticias sobre HALO_US — 223 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Sólo acción del precio: los movimientos de Halozyme Therapeutics Inc. (HALO) marcan la pauta para los modelos institucionales. Disciplina y ejecución basada en reglas en HALO Response
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") anunció hoy que publicará sus resultados financieros y operativos del tercer trimestre de 2026 el jueves 5 de noviembre de 2026, luego del cierre de operaciones.
CHRD, HALO, SEZL, SNDK y TER cuentan con sólidos márgenes y perspectivas de crecimiento, con catalizadores de ganancias por delante a medida que lleguen los resultados de octubre de 2026.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.
Second-quarter revenue reached USD 481.00 million, up 47.70 percent. Halozyme Therapeutics stock cos
Halozyme Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 73.5%, reaching $120.69 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Detailed price information for Apa Corp (APA-Q) from The Globe and Mail including charting and trades.
Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron stand out for strong share gains and rising earnings estimates under a relative price strength strategy.
Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron stand out for strong share gains and rising earnings estimates under a relative price strength strategy.
HALO gained 81.04 percent year to date by October 16, 2026. Halozyme Therapeutics stock cost USD 121
HALO gained 81.04 percent year to date by October 16, 2026. Halozyme Therapeutics stock cost USD 121
Halozyme Therapeutics (HALO) Holds Steady at $121.84 as Shares Consolidate Below Resistance - Exhaustion Gap
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Página 1 de 12